Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06046066 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of NM6603 in Advanced Solid Tumors
A Phase 1 study of Cancers, sponsored by NucMito Pharmaceuticals Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 4
- Study locations
NCT06046066: Recruiting Phase 1 study of Cancers, sponsored by NucMito Pharmaceuticals Co..
NCT06046066 is a Phase 1 study of Cancers that is actively recruiting participants, run by NucMito Pharmaceuticals Co.. The registered enrollment target is 36 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06046066, a Phase 1 study of Cancers, is actively recruiting participants, sponsored by NucMito Pharmaceuticals Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is to assess the MTD and RP2D of NM6603 in adult patients with advanced solid tumors.
Conditions Studied
Interventions
- DRUG NM6603
Study Locations (4)
Michigan
- Karmanos Cancer Institute - Detroit
Ohio
- Cleveland Clinic Taussig Cancer Center - Cleveland
Tennessee
- Tennessee Oncology, PLLC - Nashville
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2023-08-31 |
| Est. Completion | 2026-02-28 |
| Phase | Phase 1 |
What NCT06046066 shows while recruiting
NCT06046066 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower).
The record links to 1 condition, with Cancers appearing as the primary indexed condition, and to 1 intervention - of which NM6603 is the first listed.
NCT06046066 reports a single indexed study location in Michigan, Ohio, Tennessee.
Frequently Asked Questions
What is clinical trial NCT06046066 about?
NCT06046066 is a clinical study titled "A Phase 1 Study of NM6603 in Advanced Solid Tumors". This study is to assess the MTD and RP2D of NM6603 in adult patients with advanced solid tumors.
What is the current status of trial NCT06046066?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2023-08-31. Estimated completion is 2026-02-28.
What conditions does trial NCT06046066 study?
This clinical trial studies the following conditions: Cancers.
What interventions are being tested in trial NCT06046066?
The interventions under investigation include: NM6603 (DRUG).
Who is sponsoring clinical trial NCT06046066?
This trial is sponsored by NucMito Pharmaceuticals Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06046066 being conducted?
This trial has 4 study locations across Michigan, Ohio, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06046066's enrollment target sits among peer trials
36 1211th of 2000 higher than 743 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI